Publications by authors named "Ines Deleu"

Claim this Profile
E
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, Guillermo Streich, Alberto J Montero, Ines Deleu

J Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.
Elena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, Marta Rita Reforgiato, Isabella Leone, Ines Deleu

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
Robert Coleman, Dianne M Finkelstein, Carlos Barrios, Miguel Martin, Hiroji Iwata, Ines Deleu

Lancet Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Gabriel N Hortobagyi, David Chen, Martine Piccart, Hope S Rugo, Howard A Burris, Ines Deleu

J Clin Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
J Thaddeus Beck, Gabriel N Hortobagyi, Mario Campone, Fabienne Lebrun, Ines Deleu

Breast Cancer Res Treat· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
Mario Campone, Thomas Bachelot, Michael Gnant, Ines Deleu, Hope S Rugo

Eur J Cancer· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Antonio Llombart, Antonio Frassoldati, Outi Paija, Harm Peter Sleeboom, Guy Jerusalem, Ines Deleu

Clin Breast Cancer· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
José Baselga, Mario Campone, Martine Piccart, Howard A Burris, Hope S Rugo, Ines Deleu

N Engl J Med· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis